We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Halozyme Therapeutics, a development stage biopharmaceutical company developing
and commercializing recombinant human enzymes, announced it has signed a commercial
manufacturing supply agreement with Avid Bioservices, a wholly owned subsidiary
of Peregrine Pharmaceuticals.
Yamanouchi Pharmaceutical has announced that is has agreed with Daiichi Suntory
Pharma to terminate a marketing agreement between the two companies regarding
the penem-type antibiotic Farom (faropenem sodium) on March 31, 2005.
OctoPlus, the drug delivery and development company and Biolex Inc., a protein
therapeutics company, announced today that they have entered into collaboration
for co-development of a controlled release formulation of recombinant human
alfa interferon.
Kucera Pharmaceutical Co., whose cash crunch last year forced it to close its
research and administrative offices in Winston-Salem, has won a $100,000 federal
grant to pursue medical research of respiratory diseases.
Neosil, a privately held specialty dermatology company, announced that it completed
in-licensing of several hair growth products from OsteoScreen Inc., a private
company focused on drug discovery for bone diseases.
Spectrum Pharmaceuticals announced that it has acquired
an exclusive worldwide license to develop and commercialize endothelinB agonists
for the treatment of cancer, including treatment of solid tumors, from Chicago
Labs Inc., a privately held company.
The U.S. District Court for the Southern District of New York has granted summary
judgment to Barr Laboratories in its challenge to patents on desmopressin acetate
tablets. The decision effectively ends a 30-month stay on the FDA's approval
of Barr's product, the company said.
Illinois has become the latest state to sue multiple drugmakers for inflating
drug prices by overstating the average wholesale prices (AWP) of their products
under Medicaid and Medicare programs.
One of the FDA's major goals for 2005 and
2006 is to speed marketing approval times for generic drugs, but the agency
will have to accomplish that task without much of an increase in funding for
its generic drug program.
A bipartisan coalition including some of the nation's most powerful and influential
senators has introduced a bill that would allow U.S. consumers to import "safe
prescription drugs" from other countries.